Pharma companies in the U.S. have announced roughly $158B in new investments this year, most of which will be directed toward the development of new plants for manufacturing drugs of all kinds.
These plans have created a site selection race for municipalities and economic development teams across the country with decisions expected soon. Many see the competition to snag a new facility entering a final stage, with the winners possibly netting hundreds of jobs and significant tax revenue. 
“All the major pharma companies have made some kind of commitment,” NCBiotech CEO Doug Edgeton said. “I do think there is an urgency now…